Surgical aspects of inflammatory breast cancer

Breast Disease

Volumn 22, Issue , 2005, Pages 67-73

  Kell, Malcolm R ^a   Morrow, Monica ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; TUMOR MARKER; VINCRISTINE;

ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; BREAST RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFLAMMATORY BREAST CANCER; INOPERABLE CANCER; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MASTECTOMY; MULTIMODALITY CANCER THERAPY; MYOCUTANEOUS FLAP; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; WOUND HEALING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; BREAST TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745601444     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2006-22108     Document Type: Article

References (62)

1. P.H. Levine, S.C. Steinhorn, L.G. Ries and J.L. Aron, Inflammatory breast cancer: The experience of the surveillance, epidemiology, and end results (SEER) program, J Natl Cancer Inst 74 (1985), 291-297.
2. S.E. Singletary, F.C. Ames and A.U. Buzdar, Management of inflammatory breast cancer, World J Surg 18 (1994), 87-92.
3. I.A. Jaiyesimi, A.U. Buzdar and G. Hortobagyi, Inflammatory breast cancer: A review, J Clin Oncol 10 (1992), 1014-1024.
4. S. Chang, S.L. Parker, T. Pham, A.U. Buzdar and S.D. Hursting, Inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992, Cancer 82 (1998), 2366-2372.
5. K.W. Hance, W.F. Anderson, S.S. Devesa, H.A. Young and P.H. Levine, Trends in inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program at the National Cancer Institute, J Natl Cancer Inst 97 (2005), 966-975.
6. B.J. Lee and N.E. Tannenbaum, Inflammatory carcinoma of the breast, Clin Radiol 39 (1924), 580-595.
7. C.C. Wang and N.T. Griscom, Inflammatory Carcinoma of the Breast. Results Following Orthovoltage and Supervoltage Radiation Therapy, Clin Radiol 15 (1964), 167-174.
8. C.D. Haagensen and A.P. Stout, Carcinoma of the breast. III. Results of treatment, 1935-1942, Ann Surg 134 (1951), 151-170.
9. K.W. Barber, Jr., M.B. Dockerty and O.T. Clagett, Inflammatory carcinoma of the breast, Surg Gynecol Obstet 112 (1961), 406-410.
10. F. Bozzetti, R. Saccozzi, M. De Lena and B. Salvadori, Inflammatory cancer of the breast: Analysis of 114 cases, J Surg Oncol 18 (1981), 355-361.
11. A.F. Chambler, P.J. Drew, A.D. Hill, A. Darzi and J.R. Monson, Inflammatory breast carcinoma, Surg Oncol 4 (1995), 245-254.
12. G. Taylor and A. Meltzer, Inflammatory carcinoma of the breast, Am J Cancer 33 (1938), 33-49.
13. S.M. Chris, Inflammatory carcinoma of the breast; a report of 20 cases and a review of the literature, Br J Surg 38 (1950), 163-174.
14. N. Treves, The inoperability of inflammatory carcinoma of the breast, Surg Gynecol Obstet 109 (1959), 240-242.
15. C.S. Rogers and W.T. Fitts, Jr., Inflammatory carcinoma of the breast: A critique of therapy, Surgery 39 (1956), 367-370.
16. T.L. Dao and C.J. Mc Carthy, Treatment of inflammatory carcinoma of the breast, Surg Gynecol Obstet 105 (1957), 289-294.
17. B.F. Byrd, Jr. and S.E. Stephenson, Jr., Management of inflammatory breast cancer, South Med J 53 (1960), 945-948.
18. G.J. Richards, Jr. and E.F. Lewison, Inflammatory carcinoma of the breast, Surg Gynecol Obstet 113 (1961), 729-732.
19. W. Donegan, Staging and end results, in: Staging and End Results, J.S. Spratt, Jr. and W.L. Donegan, eds, Saunders, Philadelphia, 1967, pp. 117-161.
20. G.F. Robbins, J. Shah, P. Rosen, F. Chu and J. Taylor, Inflammatory carcinoma of the breast, Surg Clin North Am 54 (1974), 801-810.
21. L.H. Stocks and F.M. Patterson, Inflammatory carcinoma of the breast, Surg Gynecol Obstet 143 (1976), 885-889.
22. A.U. Buzdar, E.D. Montague, J.L. Barker, G.N. Hortobagyi and G.R. Blumenschein, Management of inflammatory carcinoma of breast with combined modality approach - an update, Cancer 47 (1981), 2537-2542.
23. C.D. Knight, Jr., J.K. Martin, Jr., J.S. Welch, J.N. Ingle, T.A. Gaffey and A. Martinez, Surgical considerations after chemotherapy and radiation therapy for inflammatory breast cancer, Surgery 99 (1986), 385-391.
24. B. Zylberberg, J. Salat-Baroux, J.H. Ravina, D. Dormont, J.P. Amiel, P. Diebold and V. Izrael, Initial chemoimmunotherapy in inflammatory carcinoma of the breast, Cancer 49 (1982), 1537-1543.
25. M.P. Moore, J.K. Ihde, J.P. Crowe, Jr., T.P. Hakes and D.W. Kinne, Inflammatory breast cancer, Arch Surg 126 (1991), 304-306.
26. B. Chevallier, H. Roche, J. P. Olivier, P. Chollet and P. Hurteloup, Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate, Am J Clin Oncol 16 (1993), 223-228.
27. J. Attia-Sobol, J.P. Ferriere, H. Cure, F. Kwiatkowski, J.L. Achard, P. Verrelle, V. Feillel, M. De Latour, C. Lafaye, C. Deloche et al., Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: Univariate and multivariate analysis, Eur J Cancer 29A (1993), 1081-1088.
28. N. Mourali, F. Tabbane, L.R. Muenz, J. Behi, F. Ben Moussa, M. Jaziri and P.H. Levine, Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer, Cancer Invest 11 (1993), 363-370.
29. F. Thomas, R. Arriagada, M. Spielmann, H. Mouriesse, T. Le Chevalier, F. Fontaine and T. Tursz, Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy, Cancer 76 (1995), 2286-2290.
30. N.T. Ueno, A.U. Buzdar, S.E. Singletary, F.C. Ames, M.D. McNeese, F.A. Holmes, R.L. Theriault, E.A. Strom, B.J. Wasaff, L. Asmar, D. Frye and G.N. Hortobagyi, Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at M. D. Anderson Cancer Center, Cancer Chemother Pharmacol 40 (1997), 321-329.
31. D.W. Arthur, R.K. Schmidt-Ullrich, R.B. Friedman, D.E. Wazer, L.A. Kachnic, C. Amir, H.D. Bear, M.H. Hackney, T.J. Smith and W. Lawrence, Jr., Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: Complete response predicts outcome and allows for breast conservation, Int J Radiat Oncol Biol Phys 44 (1999), 289-296.
32. R.H. De Boer, A. Saini, S.R. Johnston, M.E. O'Brien, P.A. Ellis, M.W. Verrill, J.A. Prendiville, G. Walsh, S. Ashley and I. E. Smith, Continuous infusional combination chemotherapy in inflammatory breast cancer: A phase II study, Breast 9 (2000), 149-155.
33. E. Baldini, G. Gardin, G. Evagelista, T. Prochilo, P, Collecchi and R. Lionetto, Long-term results of combined-modality therapy for inflammatory breast carcinoma, Clin Breast Cancer 5 (2004), 358-363.
34. T.R. Evans, A. Yellowlees, E. Foster, H. Earl, D.A. Cameron, A.W. Hutcheon, R.E. Coleman, T. Perren, C.J. Gallagher, M. Quigley, J. Crown, A.L. Jones, M. Highley, R.C. Leonard and J.L. Mansi, Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study, J Clin Oncol 23 (2005), 2988-2995.
35. M. Cristofanilli, A.U. Buzdar, N. Sneige, T. Smith, B. Wasaff, N. Ibrahim, D. Booser, E. Rivera, J.L. Murray, V. Valero, N. Ueno, E.S. Singletary, K. Hunt, E. Strom, M. McNeese, C. Stelling and G.N. Hortobagyi, Paclitaxel in the multimodality treatment for inflammatory breast carcinoma, Cancer 92 (2001), 1775-1782.
36. S.M. Swain, R.A. Sorace, C.S. Bagley, D.N. Danforth, Jr., J. Bader, M.N. Wesley, S.M. Steinberg and M.E. Lippman, Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer, Cancer Res 47 (1987), 3889-3894.
37. J.A. Low, A.W. Berman, S.M. Steinberg, D.N. Danforth, M.E. Lippman and S.M. Swain, Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy, J Clin Oncol 22 (2004), 4067-4074.
38. S.D. Merajver, B.L. Weber, R. Cody, D. Zhang, M. Strawderman, K.A. Calzone, V. LeClaire, A. Levin, J. Irani, M. Halvie, D. August, M. Wicha, A. Lichter and L.J. Pierce, Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience, J Clin Oncol 15 (1997), 2873-2881.
39. E.E. Harris, D. Schultz, H. Bertsch, K. Fox, J. Glick and L.J. Solin, Ten-year outcome after combined modality therapy for inflammatory breast cancer, Int J Radiat Oncol Biol Phys 55 (2003), 1200-1208.
40. W.W. Thoms, Jr., M.D. McNeese, G.H. Fletcher, A.U. Buzdar, S.E. Singletary and M.J. Oswald, Multimodal treatment for inflammatory breast cancer, Int J Radiat Oncol Biol Phys 17 (1989), 739-745.
41. N.A. Fastenberg, R.G. Martin, A.U. Buzdar, G.N. Hortobagyi, E.D. Montague, G.R. Blumenschein and J.M. Jessup, Management of inflammatory carcinoma of the breast. A combined modality approach, Am J Clin Oncol 8 (1985), 134-141.
42. J.N. Fields, C.A. Perez, R.R. Kuske, B.B. Fineberg and N. Bartlett, Inflammatory carcinoma of the breast: Treatment results on 107 patients, Int J Radiat Oncol Biol Phys 17 (1989), 249-255.
43. E.G. Elias, D.A. Vachon, M.S. Didolkar and J. Aisner, Long-term results of a combined modality approach in treating inflammatory carcinoma of the breast, Am J Surg 162 (1991), 231-235.
44. T.M. Pisansky, D.J. Schaid, C.L. Loprinzi, J.H. Donohue, M.F. Schray and P.J. Schomberg, Inflammatory breast cancer: Integration of irradiation, surgery, and chemotherapy, Am J Clin Oncol 15 (1992), 376-387.
45. D.A. Fein, N.P. Mendenhall, R.D. Marsh, K.I. Bland, E.M. Copeland, 3rd and R.R. Million, Results of multimodality therapy for inflammatory breast cancer: An analysis of clinical and treatment factors affecting outcome, Am Surg 60 (1994), 220-225.
46. M. Colozza, S. Gori, A.M. Mosconi, P. Anastasi, V de Angelis, M. Giansanti, U. Mercati, C. Aristei, P. Latini and M. Tonato, Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results, Am J Clin Oncol 19 (1996), 10-47.
47. C.A. Perez, J.N. Fields, P.M. Fracasso, G. Philpott, R.L. Soares, Jr., M.E. Taylor, M.A. Lockett and C. Rush, Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma, Cancer 74 (1994), 466-476.
48. R.H. De Boer, W.H. Allum, S.R. Ebbs, G.P. Gui, S.R. Johnston, N.P. Sacks, G. Walsh, S. Ashley and I.E. Smith, Multimodality therapy in inflammatory breast cancer: Is there a place for surgery? Ann Oncol 11 (2000), 1147-1153.
49. G. Cocconi, B. Di Blasio, G. Alberti, G. Bisagni, E. Botti and G. Peracchia, Problems in evaluating response of primary breast cancer to systemic therapy, Breast Cancer Res Treat 4 (1984), 309-313.
50. E.H. Koh, A.U. Buzdar, F.C. Ames, S.E. Singletary, M.D. McNeese, D. Frye, F.A. Holmes, G. Fraschini, V. Hug, R.L. Theriault et al., Inflammatory carcinoma of the breast: Results of a combined-modality approach - M.D. Anderson Cancer Center experience, Cancer Chemother Pharmacol 27, 1990, 94-100.
51. G. Hortobagyi, S.E. Singletary and E.A. Stron, Treatment of Locally Advanced and Inflammatory Breast Cancer, in: Treatment of Locally Advanced and Inflammatory Breast Cancer, J.R. Harris, M.E. Lippman and M. Morrow, eds, Lippincott, Williams & Wilkins, Philadelphia, 2000, pp. 645-660.
52. R.Y. Fleming, L. Asmar, A.U. Buzdar, M.D. McNeese, F.C. Ames, M.I. Ross and S.E. Singletary, Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma, Ann Surg Oncol 4 (1997), 452-461.
53. M. Panades, I.A. Olivotto, C.H. Speers, T. Shenkier, T.A. Olivotto, L. Weir, S.J. Allan and P.T. Truong, Evolving treatment strategies for inflammatory breast cancer: A population-based survival analysis, J Clin Oncol 23 (2005), 1941-1950.
54. R.D. Foster, L.J. Esserman, J.P. Anthony, E.S. Hwang and H. Do, Skin-sparing mastectomy and immediate breast reconstruction: A prospective cohort study for the treatment of advanced stages of breast carcinoma, Ann Surg Oncol 9 (2002), 462-466.
55. L.A. Newman, H.M. Kuerer, K.K. Hunt, F.C. Ames, M.I. Ross, R. Theriault, N. Fry, S.S. Kroll, G.L. Robb and S.E. Singletary, Feasibility of immediate breast reconstruction for locally advanced breast cancer, Ann Surg Oncol 6 (1999), 671-675.
56. S.A. Slavin, S.M. Love and R.M. Goldwyn, Recurrent breast cancer following immediate reconstruction with myocutaneous flaps, Plast Reconstr Surg 93 (1994), 1191-1204; discussion 1205-1197.
57. P.L. Chin, J.S. Andersen, G. Somlo, D.Z. Chu, R.E. Schwarz and J.D. Ellenhorn, Esthetic reconstruction after mastectomy for inflammatory breast cancer: Is it worthwhile? J Am Coll Surg 190 (2000), 304-309.
58. M.R. Kell and M.J. Kerin, Sentinel lymph node biopsy, Bmj 328 (2004), 1330-1331.
59. U. Veronesi, G. Paganelli, G. Viale, A. Luini, S. Zurrida, V. Galimberti, M. Intra, P. Veronesi, C. Robertson, P. Maisonneuve, G. Renne, C. De Cicco, F. De Lucia and R. Gennari, A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer, N Engl J Med 349 (2003), 546-553.
60. H. Charfare, S. Limongelli and A.D. Purushotham, Neoadjuvant chemotherapy in breast cancer, Br J Surg 92 (2005), 14-23.
61. E.P. Mamounas, A. Brown, S. Anderson, R. Smith, T. Julian, B. Miller, H.D. Bear, C.B. Caldwell, A.P. Walker, W.M. Mikkelson, J. S. Stauffer, A. Robidoux, H. Theoret, A. Soran, B. Fisher, D.L. Wickerham and N. Wolmark, Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol 23 (2005), 2694-2702.
62. V. Stearns, C.A. Ewing, R. Slack, M.F. Penannen, D.F. Hayes and T.N. Tsangaris, Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer, Ann Surg Oncol 9 (2002), 235-242.